Scinopharm Taiwan (TPE:1789) Cyclically Adjusted Revenue per Share: NT$4.90 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1789 Scinopharm Taiwan Ltd TPE:1789
70 GF Score
Price NT$19.65
GF Value NT$24.86
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Scinopharm Taiwan Cyclically Adjusted Revenue per Share?

Scinopharm Taiwan TPE:1789 -0.76% 70 Cyclically Adjusted Revenue per Share is NT$4.90 as of Mar. 2026. GuruFocus rates TPE:1789 with a GF Score™ of 70/100 and a GF Value™ of NT$24.86 (Modestly Undervalued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Scinopharm Taiwan's adjusted revenue per share for the three months ended in Mar. 2026 was NT$0.834. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$4.90 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Scinopharm Taiwan's average Cyclically Adjusted Revenue Growth Rate was -2.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -3.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -1.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Scinopharm Taiwan was -1.00% per year. The lowest was -3.40% per year. And the median was -2.30% per year.

As of today (2026-07-24), Scinopharm Taiwan's current stock price is NT$19.65. Scinopharm Taiwan's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$4.90. Scinopharm Taiwan's Cyclically Adjusted PS Ratio of today is 4.01.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Scinopharm Taiwan was 7.18. The lowest was 3.33. And the median was 4.73.


Scinopharm Taiwan  (TPE:1789) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Scinopharm Taiwan's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=19.65/4.90
=4.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Scinopharm Taiwan was 7.18. The lowest was 3.33. And the median was 4.73.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Scinopharm Taiwan Cyclically Adjusted Revenue per Share Related Terms


Scinopharm Taiwan Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan Cyclically Adjusted Revenue per Share Chart

Scinopharm Taiwan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.42 5.44 5.18 5.06 4.90

Scinopharm Taiwan Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.04 5.01 4.97 4.90 4.90

TPE:1789 vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Scinopharm Taiwan's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scinopharm Taiwan Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scinopharm Taiwan's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Scinopharm Taiwan's Cyclically Adjusted PS Ratio falls into.


TPE:1789
70GF Score
Scinopharm Taiwan Ltd TPE:1789
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scinopharm Taiwan Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Scinopharm Taiwan's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.834/330.2130*330.2130
=0.834

Current CPI (Mar. 2026) = 330.2130.

Scinopharm Taiwan Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.287 241.018 1.763
201609 1.258 241.428 1.721
201612 1.260 241.432 1.723
201703 1.159 243.801 1.570
201706 1.112 244.955 1.499
201709 1.111 246.819 1.486
201712 1.130 246.524 1.514
201803 1.087 249.554 1.438
201806 1.278 251.989 1.675
201809 0.990 252.439 1.295
201812 1.081 251.233 1.421
201903 0.974 254.202 1.265
201906 0.757 256.143 0.976
201909 0.849 256.759 1.092
201912 1.036 256.974 1.331
202003 0.685 258.115 0.876
202006 1.120 257.797 1.435
202009 0.992 260.280 1.259
202012 1.103 260.474 1.398
202103 0.809 264.877 1.009
202106 0.907 271.696 1.102
202109 0.741 274.310 0.892
202112 0.907 278.802 1.074
202203 0.932 287.504 1.070
202206 0.991 296.311 1.104
202209 0.931 296.808 1.036
202212 1.280 296.797 1.424
202303 0.819 301.836 0.896
202306 0.928 305.109 1.004
202309 0.859 307.789 0.922
202312 1.414 306.746 1.522
202403 1.135 312.332 1.200
202406 0.916 314.175 0.963
202409 0.802 315.301 0.840
202412 1.304 315.605 1.364
202503 0.866 319.799 0.894
202506 0.874 322.561 0.895
202509 0.934 324.800 0.950
202512 1.272 324.054 1.296
202603 0.834 330.213 0.834

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$4.90 mean?
Scinopharm Taiwan (TPE:1789) has a Cyclically Adjusted Revenue per Share of NT$4.90 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's Cyclically Adjusted Revenue per Share too high?
Scinopharm Taiwan's current Cyclically Adjusted Revenue per Share is NT$4.90. Overall, Scinopharm Taiwan has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Scinopharm Taiwan's Cyclically Adjusted Revenue per Share of NT$4.90 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current Cyclically Adjusted Revenue per Share is NT$4.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$24.86, compared to a current price of NT$19.65 — trading 21% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$4.90. Scinopharm Taiwan's overall GF Score™ is 70/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current Cyclically Adjusted Revenue per Share is NT$4.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$19.65 is trading 21% below its estimated GF Value™ of NT$24.86. GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.

Key valuation signals for TPE:1789:

  • Cyclically Adjusted Revenue per Share: NT$4.90
  • GF Value™: NT$24.86 vs. price of NT$19.65 (21% below fair value)
  • GF Score™: 70/100 with 9 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
70GF Score

Get the complete analysis for TPE:1789

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$19.65
Price
NT$24.86
GF Value